Conflict-of-interest disclosure: P.F.C. has received research funding from ADC Therapeutics, Genentech, and AbbVie and honoraria for participation in advisory boards/consulting from ADC Therapeutics, Beigene, BMS, Genentech, Kite, Lilly, MEI Pharma, Novartis, and Takeda. D.A.B. has received research funding from Incyte/Morphosys, Novartis, and Nurix Therapeutics and honoraria for consulting from SeaGen, Kite/Gilead, Nurix Therapeutics, and Novartis. L.L. has received honoraria for consulting and/or participation in speaker bureau from Kite/Gilead, Beigene, Pharmacyclics, AbbVie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lilly, Epizyme, TG Therapeutics, Merck, and ADC Therapeutics. L.J.N. has received honoraria for participation in advisory boards/consulting from AbbVie, ADC Therapeutics, Atara Biotherapeutics, BMS/Celgene, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech/Roche, Genmab, Janssen, Incyte, Morphosys, Novartis, and Takeda and research support from BMS/Celgene, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech/Roche, Genmab, Gilead/Kite, IGM Biosciences, Janssen, Novartis, and Takeda. J.L.C. has received research support (to institution) from Genentech, Merck, Bayer, and AbbVie and honoraria for consulting from ADC Therapeutics, Kite Pharma, Genmab, and Incyte/MorphoSys. J.S.A. has received honoraria for consulting from AbbVie, AstraZeneca, BeiGene, BMS, Caribou Biosciences, Cellectar, Century Therapeutics, Epizyme, Genentech, Genmab, Incyte, Interius, Janssen, Kite Pharma, Kymera, Lilly, MorphoSys, Mustang Bio, Ono Pharma, Regeneron, and Takeda and research support (to institution) from BMS, Cellectis, Merck, Mustang Bio, and Seattle Genetics. G.S.N. has received honoraria for consultancy from AbbVie, ADC Therapeutics, Bantam Pharmaceutical LLC, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis, Debiopharm, F. Hoffmann-La Roche Limited, Fate Therapeutics, Genentech, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys AG, Ryvu Therapeutics, Seagen, Selvita Inc, TG Therapeutics, and Zai Lab Limited and research funding from Bristol Myers Squibb and MorphoSys and is a member on a board of directors or advisory committee for Karyopharm Therapeutics, Ryvu Therapeutics, and Fate Therapeutics. K.M. has received research funding from Pharmacyclics, Novartis, Merck, BMS, and Celgene and honoraria for consulting from AbbVie, ADC Therapeutics, AstraZeneca, BMS, Celgene, Gilead/Kite, GenMab, Genentech, Incyte, Janssen, Merck, Morphosys, Lilly, and Pharmacyclics. S.C.R. has received research funding from Constellation, Karyopharm, and Genentech/Roche and honoraria for consulting from ADC, Genmab, Karyopharm, Kite, and Seagen. B.K. has received honoraria for consulting from AbbVie, AstraZeneca, ADCT, BeiGene, BMS, Genentech, Genmab, Gilead, Janssen, and Lilly and research funding from Genentech, ADCT, AstraZeneca, and BeiGene. C.L.B. is currently employed at Roche/Genentech; participation in the study occurred prior to employment at Roche/Genentech. G.S. has received, in the last 12 months, financial compensation for participating in advisory boards or consulting from AbbVie, ATB Therapeutics, Beigene, BMS/Celgene, Debiopharm, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Merck, Molecular Partners, Nordic Nanovector, Novartis, Nurix, and Orna; is shareholder of Owkin; and has received research support managed by his institution from Genentech, Janssen and Ipsen. The remaining authors declare no competing financial interests.

The current affiliation for C.L.B. is Roche/Genentech, San Francisco, CA.